Medivir

Medivir FCF/Debt

The Free Cash Flow to Debt Ratio of Medivir (MVIR.ST) as of Oct 16, 2026 is -368.37 %. In the previous year, Free Cash Flow to Debt Ratio was -341.12 % — a change of 7.99% (lower).

FCF/Debt

-368.37 %

YoY

7.99%

Last updated:

Free Cash Flow to Debt Ratio of Medivir is 2020 -368.37 % . Free Cash Flow to Debt Ratio of Medivir was 2019 -341.12 % . It decreases by 7.99% lower compared to the previous year.

The Medivir FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2014
2,485.50 SEK
Jan 1, 2019
-341.12 SEK
Jan 1, 2020
-368.37 SEK
The Medivir FCF/Debt history
YEARFCF/DebtYoY
-368.37 %+7.99%
-341.12 %-113.72%
2,485.50 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medivir Stock analysis

What does Medivir do? Medivir AB is a biotechnology company based in Huddinge, Sweden, operating within the health care sector. The company has a small team of nine full-time employees. Founded in 1996, Medivir AB went public on February 29, 1996, and is listed on the Stockholm Stock Exchange under the ticker MVIR.ST. The company's website is www.medivir.se. Medivir focuses on the development of pharmaceutical products, particularly in the areas of protease inhibitor design and nucleoside and nucleotide science. Their clinical pipeline includes remetinostat, a topical histone deacetylase inhibitor in phase II trials for cutaneous T-cell lymphoma, and birinapant combined with Keytruda for solid tumors in phase I trials. Additionally, MIV-818, a nucleotide-based prodrug, is in phase I trials for liver cancer, and MIV-711, a cathepsin K inhibitor, is in an IIa extension study for osteoarthritis. The company collaborates with other institutions on research projects. Medivir AB is dedicated to addressing unmet medical needs through innovative therapeutic approaches. Medivir is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medivir stock

Free Cash Flow to Debt Ratio of Medivir is -368.37 % in 2020.

Free Cash Flow to Debt Ratio of Medivir changed from -341.12 % to -368.37 %, representing a 7.99% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Medivir since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Medivir with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Medivir

All Key Metrics — Medivir